CYTK · XBRL financial data

Cytokinetics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CYTK's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	56	70	95	8	18	88
Research and development	97	160	241	330	339	416
General and administrative	53	97	178	174	215	284
Total operating expenses	150	257	419	504	555	700
Operating income (loss)	(94)	(186)	(324)	(496)	(536)	(612)
Interest income	5	1	11	—	—	—
Interest expense	16	16	19	28	38	46
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(127)	(215)	(389)	(526)	(590)	(785)
Earnings per share, basic USD per share	(1.97)	(2.80)	(4.33)	(5.45)	(5.26)	(6.54)
Earnings per share, diluted USD per share	(1.97)	(2.80)	(4.33)	(5.45)	(5.26)	(6.54)
Weighted average shares, basic millions of shares	0	0	0	0	0	0
Weighted average shares, diluted millions of shares	0	0	0	0	0	0

Fiscal years (CYTK's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	83	113	66	113	95	123
Marketable securities	381	359	717	502	981	760
Marketable securities, non-current	37	152	47	41	145	335
Accounts receivable	4	52	0	1	17	18
Inventory	—	—	—	—	—	0
Prepaid and other current assets	6	12	12	12	15	17
Total current assets	474	536	795	628	1,108	917
Property and equipment, net	13	73	80	69	66	79
Right-of-use asset	3	73	83	79	75	76
Total assets	534	841	1,015	824	1,402	1,425
Accounts payable	8	21	26	22	20	22
Accrued liabilities	19	34	44	43	55	83
Current portion of long-term debt	0	—	1	10	12	41
Total current liabilities	31	72	85	103	180	202
Long-term debt	46	47	64	58	93	246
Lease liability, non-current	0	112	127	120	113	108
Total liabilities	420	597	1,123	1,211	1,537	2,084
Accumulated deficit	(992)	(1,208)	(1,586)	(2,112)	(2,702)	(3,487)
Total stockholders' equity	113	244	(108)	(386)	(135)	(660)
Total liabilities and equity	534	841	1,015	824	1,402	1,425
Common shares outstanding (cover page) millions of shares	71	85	95	103	118	123

Fiscal years (CYTK's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(127)	(215)	(389)	(526)	(590)	(785)
Stock-based compensation	18	27	48	72	98	112
Depreciation and amortization	2	2	6	12	10	10
Net cash from operating activities	9	(143)	(300)	(414)	(396)	(510)
Purchases of property and equipment	11	49	11	1	4	25
Net cash from investing activities	(197)	(148)	(262)	239	(553)	17
Proceeds from issuing common stock	0	0	—	164	—	—
Repayments of long-term debt	0	0	48	0	9	11
Net cash from financing activities	234	320	516	221	931	524
Net change in cash	47	30	(45)	46	(18)	30

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Cytokinetics	255	29	(160)*	139.0M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
TG Therapeutics	483	240	39*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	756	149	60	122.4M	—	Q1 FY26 10-QMar 31, 2026
Summit Therapeutics	419	not reported	(141)*	797.7M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	120	not reported	(95)*	96.8M	9.8 quarters	Q2 FY26 10-QJun 30, 2026
Twist Bioscience	117	not reported	1.1*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Acadia Pharmaceuticals	385	308	101*	172.3M	—	Q2 FY26 10-QJun 30, 2026
Protagonist Therapeutics	420	213	219*	64.7M	—	Q2 FY26 10-QJun 30, 2026
Prestige Consumer Healthcare	89	266	71	47.4M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.